ALFR.Y Stock Overview
Through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Alfresa Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥13.42 |
| 52 Week High | JP¥13.42 |
| 52 Week Low | JP¥13.42 |
| Beta | 0.22 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALFR.Y | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -0.2% |
| 1Y | n/a | -10.7% | 25.8% |
Return vs Industry: Insufficient data to determine how ALFR.Y performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how ALFR.Y performed against the US Market.
Price Volatility
| ALFR.Y volatility | |
|---|---|
| ALFR.Y Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALFR.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALFR.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 11,925 | Ryuji Arakawa | www.alfresa.com |
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies.
Alfresa Holdings Corporation Fundamentals Summary
| ALFR.Y fundamental statistics | |
|---|---|
| Market cap | US$2.42b |
| Earnings (TTM) | US$217.25m |
| Revenue (TTM) | US$18.18b |
11.2x
P/E Ratio0.1x
P/S RatioIs ALFR.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALFR.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥2.60t |
| Cost of Revenue | JP¥2.41t |
| Gross Profit | JP¥186.60b |
| Other Expenses | JP¥155.53b |
| Earnings | JP¥31.06b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 07, 2022
| Earnings per share (EPS) | 153.50 |
| Gross Margin | 7.18% |
| Net Profit Margin | 1.20% |
| Debt/Equity Ratio | 0.006% |
How did ALFR.Y perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/09/18 11:53 |
| End of Day Share Price | 2022/06/21 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alfresa Holdings Corporation is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshihide Yoda | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Yuki Yamazaki | Daiwa Securities Co. Ltd. |